Glioblastoma multiforme: Research Studies
5 Related Result(s)
(PROGRESS) A Phase I and Open Label, Randomized, Controlled Phase II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
The blood brain barrier (BBB) is a major obstacle to drug delivery in the treatment of malignant brain tumors including Glioblastoma multiforme (GBM). MRI...
(ATTAC-II) A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells with Tetanus-Diphtheria Toxoid Vaccine in Patients with Newly-Diagnosed Glioblastoma
The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific...
(2-THE-TOP) Phase 2, Single Arm, Historically Controlled Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (OptuneÂ®) Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma
Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults. Despite an aggressive...
Dendritic Cell (DC) and Tumor-Specific Cytotoxic T Cell (CTL) Generation Protocol from Healthy Volunteers and Patients with Malignant Brain Tumors
The purpose of this project is to perform a series of studies aimed at developing a dendritic cell-based vaccine for patients with malignant brain tumors. In...
NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
The purpose of the study is to determine if dose-escalated and -intensified photon IMRT or Proton beam therapy (using a dose-per-fraction escalation with...
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.